
Omeros Corporation (NASDAQ:OMER – Free Report) – Research analysts at HC Wainwright raised their FY2027 earnings per share estimates for Omeros in a research report issued on Tuesday, November 17th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will post earnings of $0.33 per share for the year, up from their previous estimate of $0.24. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.08) per share.
Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $22.00 price target on shares of Omeros in a research report on Wednesday, October 14th. Weiss Ratings upgraded shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $30.33.
Omeros Trading Down 3.7%
NASDAQ OMER opened at $14.01 on Wednesday. The firm has a market capitalization of $1.01 billion, a PE ratio of 4.88 and a beta of 2.96. The business’s 50-day moving average price is $17.93 and its two-hundred day moving average price is $13.80. Omeros has a 12 month low of $6.70 and a 12 month high of $21.24.
Omeros (NASDAQ:OMER – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.04. The business had revenue of $35.93 million during the quarter, compared to analyst estimates of $37.28 million.
Hedge Funds Weigh In On Omeros
Institutional investors have recently added to or reduced their stakes in the business. Algert Global LLC acquired a new stake in Omeros in the third quarter worth $1,234,000. New York State Common Retirement Fund increased its stake in Omeros by 25.6% in the third quarter. New York State Common Retirement Fund now owns 26,013 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 5,300 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in Omeros in the third quarter valued at $733,000. Goldman Sachs Group Inc. increased its stake in Omeros by 151.6% in the third quarter. Goldman Sachs Group Inc. now owns 395,032 shares of the biopharmaceutical company’s stock valued at $7,521,000 after purchasing an additional 238,024 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of Omeros during the third quarter valued at about $3,387,000. 48.79% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Omeros
In related news, VP Peter B. Cancelmo sold 25,000 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the sale, the vice president owned 200 shares in the company, valued at $3,708. This represents a 99.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arnold C. Hanish sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the sale, the director directly owned 5,000 shares of the company’s stock, valued at $94,750. This represents a 66.67% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 75,906 shares of company stock valued at $1,438,705. Corporate insiders own 10.50% of the company’s stock.
More Omeros News
These are some of the OMER news items that stood out recently:
- Positive Sentiment: HC Wainwright reiterated its Buy rating and $33 price target, raising estimates for FY2026, FY2027, FY2029 and FY2030 earnings. Its FY2028 estimate was trimmed, so the revisions were not uniformly positive. HC Wainwright estimate changes
- Positive Sentiment: Recent earnings-call coverage highlights YARTEMLEA growth and commercial momentum, which could support future revenue if the product’s rollout continues. Omeros earnings call highlights YARTEMLEA growth
- Negative Sentiment: Coverage of the stock’s move points to the quarterly results and investor concerns as near-term drivers, leaving the shares under pressure despite analyst optimism. Why Omeros stock moved
Omeros Company Profile
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
Read More
- Five stocks we like better than Omeros
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
